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Abstract: Proteasomal dysfunction is known to be associated with amyotrophic lateral sclerosis and
frontotemporal degeneration (ALS/FTD). Our previous reports have shown that a mutant form of
ubiquilin-2 (UBQLN2) linked to ALS/FTD leads to neurodegeneration accompanied by accumu-
lations of the proteasome subunit Rpt1 in transgenic rats, but the precise pathogenic mechanisms
of how this mutation impairs the proteasome remains to be elucidated. Here, we reveal that this
UBQLN2 mutation in rats disrupted the proteasome integrity prior to neurodegeneration, that it
dissociated the 26S proteasome in vitro, and that its depletion did not affect 26S proteasome assembly.
During both disease progression and in an age-dependent manner, we found that proteasome sub-
units were translocated to the nucleus, including both of the 20S core particles (PSMA1 and PSMB7)
and the 19S regulatory particles (Rpt1 and Rpn1), suggesting that defective proteasome function may
result from the proteasome-subunit mislocalization. Taken together, the present data demonstrate
that impaired proteasome assembly is an early event in the pathogenesis of UBQLN2-associated
neurodegeneration in mutant UBQLN2 rats.
Keywords: ALS; FTD; UBQLN2; proteasome; protein aggregation; rat
1. Introduction
Protein aggregation is one of the core features in both ubiquilin-2 (UBQLN2)-associated
amyotrophic lateral sclerosis and frontotemporal degeneration (ALS/FTD) [1–3], a phe-
nomenon that has been well replicated in transgenic rodents [4–8]. UBQLN2, a member of
the UBQLN family, is involved in protein degradation via autophagy and the ubiquitin–
proteasome pathway [9–12].
Pathogenic gene mutations in UBQLN2 are also known to lead to ALS and FTD
in human patients [1,13]. As UBQLN2 interacts with microtubule-associated protein
1A/B-light chain 3 (LC3) via its ubiquitin-associated domain to regulate the formation of
autophagic vacuoles [14]. It is interesting that recent reports implicate ALS/FTD-linked
UBQLN2 mutations in proteasome dysfunction [15,16] and compromised autophagy in
transgenic rodents with UBQLN2 mutations [4–6]. Together, these reports suggest that
UBQLN2 mutations impair both autophagy and proteasome pathways.
Proteasomes are important for protein homeostasis and degrading aberrant or old
proteins and damaged organelles [17]. Compared to the partial proteasome 20S, fully
assembled proteasomes (the 26S: containing a 20S core particle with either one or two 19S
regulatory particles) are more important for maintaining protein homeostasis, and their
dysfunction is closely related to neurodegeneration [18–20]. While the 20S particle has all
the proteases of a proteasome, the 19S particle has no protease activity but is necessary for
the recognition/input of complex substrates [18–20]. Similarly, unstructured peptides can
be degraded by the 20S particle alone, but complex substrates must first be unfolded by
the 19S particle before being processed by the 20S particle for degradation [18–20].
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The UBQLN2 gene is an X-linked, and the protein has an N-terminal ubiquitin-like
domain and a C-terminal ubiquitin-associated (UBA) domain [21,22]. Both the UBL and
the UBA domains participate in the interaction with proteasomes and are involved in au-
tophagic protein degradation [14,23]. Via these domains, UBQLN2 shuttles ubiquitinated-
proteins to proteasomes for degradation [24]. In transgenic mice, the accumulations of
several proteasome subunits were caused by mutant UBQLN2 and these colocalized with
UBQLN2 positive aggregates [4]. The depletion of the 26S proteasome was reported to
cause neurodegeneration in mice [25], suggesting that 26S proteasome is necessary for
normal neuronal survival. Osaka et al. reported that ALS/FTD-linked UBQLN2 mutations
led to the in vitro accumulation of ubiquitinated-proteins in Neuro2a cells [15], again impli-
cating UBQLN2 mutations in proteasome impairment. We similarly reported that mutant
UBQLN2 transgenic rats accumulated both the autophagy substrate sequestosome-1/p62
and the proteasome regulatory subunit 7 (PSMC2, also called Rpt1) [26]. All these in vitro
and in vivo studies suggest that proteasome impairments and gain-of-toxic function are
caused by ALS/FTD-linked UBQLN2 mutations. However, the precise mechanisms by
which UBQLN2 mutations affect proteasome function are still not known. Here, we exam-
ined the effect of an ALS/FTD-linked UBQLN2 mutant on the proteasome integrity and
found that impaired proteasome assembly occurs prior to neurodegeneration in mutant
UBQLN2 transgenic rats and that no proteasome alterations were observed in UBQLN2-
depleted rats.
2. Results
2.1. Proteasome Impairment in Mutant UBQLN2 Transgenic Rats
We previously reported that an ALS/FTD-linked UBQLN2 mutation led to both
neuronal death [6] and the accumulation of proteasome subunit Rpt1 in rats [26]. In these
rats, embryonic transgene expression was suppressed using 50 µg/mL doxycycline (DOX)
in drinking water, and the DOX was deprived from the drinking water after birth. To study
the effect of mutant UBQLN2 on proteasome function, we examined both proteasome
activity and assembly in these rats. The overall proteasome activity was measured using
proteasome assay buffer with either Boc-LRR-AMC substrate, Suc-LLVY-AMC substrate,
or Z-LLE-AMC substrate for trypsin-, chymotrypsin-, or caspase-like proteasome activity,
respectively. Based on the protein-lysate samples, we observed that overall frontal-cortex
proteasome activity was unaltered until 20 weeks of age, but then worsened to the age of
40 weeks, with identical results obtained for the three different substrates (Figure 1A). These
in vivo results indicate that proteasome activity was impaired during the late stages of the
disease caused by mutant UBQLN2 expression in rats. Proteasome integrity was assessed
using in-gel assay with the Suc-AMC substrate, followed by immunoblot assessment using
the Rpt1 antibody. We found that 26S proteasomes that included a single regulatory subunit
(26S-RP1) and two regulatory subunits (26S-RP2) were decreased in mutant UBQLN2 rats
as early as four weeks of age and further deteriorated with age (Figure 1B,C). As previously
described, mutant UBQLN2 has been shown to cause neurodegeneration in rats by 18 weeks
of age. The present findings suggest that proteasome impairment precedes neuronal loss
in mutant UBQLN2 rats.
Int. J. Mol. Sci. 2021, 22, 4319 3 of 11




Figure 1. Impaired proteasome assembly in mutant UBQLN2 rats. (A). The overall activity of proteasomes was measured 
using sensitive fluorogenic substrates (Boc-AMC, Suc-AMC, or Z-AMC). The data are reported as the mean ± standard 
deviation (N = 4), * p < 0.05. (B). The in-gel assay (Suc-AMC) revealed that 26S proteasome assembly was impaired in 
mutant UBQLN2 rats, and in the immunoblot analysis using the Rpt1 antibody and 3–12% NativePAGE. Rat forebrains 
was homogenized in native protein lysis buffer, and 50 µg of total protein lysates were examined for the analysis. 26S-
RP1/RP2: 26S proteasome containing either one or two regulatory subunits. (C). Immunoblot by SDS-PAGE showing 
UBQLN2 expression levels. Of total protein lysates 10 µg were assessed and the GAPDH signal was used as the loading 
control. RatUB2: endogenous UBQLN2; huUB2: human UBQLN2. 
2.2. No Observed Alterations of Proteasome in UBQLN2-Depleted Rats 
The complete loss of UBQLN2 does not exhibit any behavioral or pathological alter-
ations in rats at 10 months of age [6]. To examine the effect of UBQLN2 loss on proteasome 
function, a total proteasome activity assessment and an in-gel assay assessment were both 
performed using UBQLN2-knockout rats. No overt changes were detected either in pro-
teasome activity or in proteasome integrity, even at an 18-month time point (Figure 2). 
Together with the results from the mutant UBQLN2 rats, these findings are consistent with 
the idea that mutant UBQLN2 causes neurodegeneration via a gain-of-toxicity function. 
Figure 1. I paired proteaso e asse bly in utant B L 2 rats. ( ). The overall activity of proteaso es as easured
using sensitive fluorogenic substrates (Boc-AMC, Suc-AMC, or Z-AMC). The data are reported as the mean ± standard
deviation (N = 4), * p < 0.05. (B). The in-gel assay (Suc-AMC) revealed that 26S proteasome assembly was impaired in
mutant UBQLN2 rats, and in the immunoblot analysis using the Rpt1 antibody and 3–12% NativePAGE. Rat forebrains was
homogenized in native protein lysis buffer, and 50 µg of total protein lysates were examined for the analysis. 26S-RP1/RP2:
26S proteasome containing either one or two regulatory subunits. (C). Immunoblot by SDS-PAGE showing UBQLN2
expression levels. Of total protein lysates 10 µg were assessed and the GAPDH signal was used as the loading control.
RatUB2: endogenous UBQLN2; huUB2: human UBQLN2.
2.2. No Observed Alterations of Proteasome in UBQLN2-Depleted Rats
The complete loss of UBQLN2 does not exhibit any behavioral or pathological alter-
ations in rats at 10 months of age [6]. To examine the effect of UBQLN2 loss on proteasome
function, a total proteasome activity assessment and an in-gel assay assessment were
both performed using UBQLN2-knockout rats. No overt changes were detected either in
proteasome activity or in proteasome integrity, even at an 18-month time point (Figure 2).
Together with the results from the mutant UBQLN2 rats, these findings are consistent with
the idea that mutant UBQLN2 causes neurodegeneration via a gain-of-toxicity function.
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Figure 2. No observed proteasomal impairment in UBQLN2 knock-out rats. (A). The proteasome activity was measured 
using the Suc-AMC substrate. The data are reported as the mean ± standard deviation (N = 4). NS: no significant difference. 
(B). The in-gel assay revealed that 26S proteasome assembly was unchanged in UBQLN2 knock-out (KO) rats. Rat fore-
brains were homogenized in native protein lysis buffer and 50 µg of total protein lysates were assessed. 
2.3. Mislocalized Proteasome Subunits in Mutant UBQLN2 Transgenic Rats 
Increasingly, evidence has implicated ALS/FTD-linked UBQLN2 mutations to be the 
cause of proteasomal impairment [4,10,16,26], and the formation of protein inclusions has 
been demonstrated in mutant UBQLN2 rats [6,26]. To examine whether mutant UBQLN2 
leads to mislocalization of proteasome subunits, tissue lysates from rat frontal cortex were 
separated into nuclear and cytoplasmic fractions. In line with our previous study [6], we 
observed that both human and rat UBQLN2 proteins were enriched in the nuclear fraction 
of mutant UBQLN2 rats at 40 weeks of age instead of 4 weeks of age (Figure 3). In addition 
to the mislocalization of the UBQLN2 protein, a variety of proteasome subunits (e.g., 
PSMA1, PSMB7, Rpt1, and Rpn1) were also translocated to the nucleus (Figure 3). To con-
firm these findings, immunofluorescence staining was used to assess tissue localization, 
and nuclear colocalization of PSMB7 was observed (Figure 4). These data suggest that 
mutant UBQLN2 promote the translocation of proteasome subunits to rat nuclei. 
 
Figure 3. Altered proteasome subunit expression in mutant UBQLN2 rats. Cell fractionation revealed the expressions of 
proteasome subunits. Rat forebrains were dissected from mutant Ubqln2 transgenic (TG) and non-transgenic (Ctr) rats and 
tissue lysates were fractionated into nuclear and cytoplasmic components. The nucleus marker (histone 3: H3) and the 
cytoplasmic marker (GAPDH) were used to determine fractionation effectiveness. Human UBQLN2 and rat Ubqln2 (Ub2) 
were detected as two separate bands. The proteasome subunits PSMA1, PSMB7, Rpt1, and Rpn1 were examined in 4-
week-old rats (A) and in 40-week-old rats (B). 
Fig re 2. o observe roteaso al i air ent in 2 knock-o t rats. ( ). he roteaso e activity as eas re
using the Suc-AMC substrate. The data are reported as the mean ± standard deviation (N = 4). NS: no significant difference.
(B). The in-gel assay revealed that 26S proteasome assembly was unchanged in UBQLN2 knock-out (KO) rats. Rat forebrains
were homogenized in native protein lysis buffer and 50 µg of total protein lysates were assessed.
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proteasome subunits. Rat forebrains were dissected from mutant UBQLN2 transgenic (TG) and non-transgenic (Ctr) rats
and tissue lysates were fractionated into nuclear and cytoplasmic components. The nucleus marker (histone 3: H3) and
the cytoplasmic marker (GAPDH) were used to determine fractionation effectiveness. Human UBQLN2 and rat Ubqln2
(Ub2) were detected as two separate bands. The proteasome subunits PSMA1, PSMB7, Rpt1, and Rpn1 were examined in
4-week-old rats (A) and in 40-week-old rats (B).
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Figure 4. Proteasome subunit PSMB7 localization in mutant UBQLN2 rats. immunofluorescence staining showed that 
PSMB7 was mislocalized to nuclei in the frontal cortex sections from 40-week-old mutant UBQLN2 rats (yellow arrows). 
Scale bars 30 μm. 
2.4. In Vitro Dissociation of the 26S Proteasome by Mutant UBQLN2 
Several in vitro and in vivo reports have implicated mutant UBQLN2 in impaired 
proteasome functions [4,10,16,26]. In the present UBQLN2 transgenic rats, 26S proteasome 
integrity was impaired as early as four weeks of age (Figure 1). To examine whether the 
mutant UBQLN2 was responsible for proteasome dissociation, we incubated 4 µg of pu-
rified 26S proteasome with 30 µg of native protein lysate from 4-week-old rats at 37 °C for 
different amounts of time. We then assessed proteasome activity in these samples using 
the Suc-AMC substrate, and observed that the overall proteasome activity was unchanged 
(Figure 5A). However, the in-gel assay revealed that proteasome 26S-RP2 (containing two 
regulatory particles) decreased dramatically after three hours of incubation. Similar re-
sults were obtained by immunoblot analysis using the Rpt1 antibody, which showed that 
19S was slightly elevated at the one-hour incubation time point but significantly elevated 
greatly at the three-hour time point (Figure 5B,C). These results were consistent with our 
previous finding that impairment of proteasome assembly occurred prior to compromised 
proteasome activity (Figure 1), and suggest that the ALS/FTD-linked UBQLN2 mutation 
dissociates 26S proteasome into 20S and 19S particles. 
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purified 26S proteasome with 30 µg of native protein lysate from 4-week-old rats at 37 ◦C
for different amounts of time. We then assessed proteasome activity in these sa ples using
the Suc- substrate, and observed that the overall proteaso e activity as unchanged
(Figure 5A). o ever, the in-gel assay revealed that proteaso e 26S-RP2 (containing t o
regulatory particles) decreased dramatically after three hours of incubation. Similar results
were obtained by immunoblot analysis using the Rpt1 antibody, which showed that 19S
was slightly elevated at the one-hour incubation time point but significantly elevated
greatly at the three-hour time point (Figure 5B,C). These results were consistent with our
previous finding that impairment of proteasome assembly occurred prior to compromised
proteasome activity (Figure 1), and suggest that the ALS/FTD-linked UBQLN2 mutation
dissociates 26S proteasome into 20S and 19S particles.
2.5. ALS/FTD-Linked UBQLN2 Mutations Did Not Affect Proteasome Function in
HEK-293T Cells
To further examine the effects of ALS/FTD-linked UBQLN2 mutations on proteasome
functions, wild-type or mutant UBQLN2 (P497H, P497S, P506T, P509S, or P525S) were
overexpressed in HEK-293T cells. We harvested cells at 48 h of after the transfection,
and three fluorogenic substrates (Suc-AMC, Boc-AMC, or Z-AMC) were used to assay
proteasome activity. None of the assays using these three substrates showed alterations,
illustrated only by the Suc-AMC data (Figure 6A). The five mutations used for these assays
were first reported by Deng et al. [1]. We then resolved the native protein lysates with
Native-PAGE but found no alterations detected either by in-gel assay or by immunoblot
using the Rpt1 antibody (Figure 6B). These results are consistent with a previous report that
proteasome activity (chymotrypsin-like activity) was not altered by these five UBQLN2
mutations in Hela cells [16].
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Figure 5. In vitro dissociation of the 26S proteasome by mutant UBQLN2. (A). The overall activity of proteasomes was 
measured using the sensitive fluorogenic substrate Suc-AMC. The data are reported as the mean ± standard deviation (N 
= 3) and showed no significant difference. (B). Purified 26S proteasome was incubated with native protein lysates for the 
times (hr) indicated, followed by in-gel assay assessment using the proteasome substrate Suc-AMC and immunoblot anal-
ysis using indicated antibodies for either NativePAGE or SDS-PAGE. (C). Based on the Panel B data, the relative ratios of 
the 26S or the 19S to the 20S proteasome were calculated by Image-J software (the NT rat value was designated as 1). This 
analysis showed that mutant UBQLN2 led to reduction of 26S proteasome but a 19S proteasome increase. NT: non-trans-
genic rats; TG: mutant UBQLN2-P497H rats; 26S-RP1/26S-RP2: 26S containing one or two regulatory subunits. 
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Figure 5. In vitro dissociation of the 26S proteasome by mutant UBQLN2. (A). The overall activity of proteasomes was
measured using the sensitive fluorogenic substrate Suc-AMC. The data are reported as the mean ± standard deviation
(N = 3) and showed no significant difference. (B). Purified 26S proteasome was incubated with ative pr tein lysates for
the times (hr) indicated, followed by in-gel assay assessment using the prot as me substrate Suc-AMC and immunoblot
analysis using indicated antibodies for either NativePAGE or SDS-PAGE. (C). Based on the Panel B data, the relative
ratios of the 26S or the 19S to the 20S proteasome were calculated by Image-J software (the NT rat value was designated
as 1). This analysis showed that mutant UBQLN2 led to reduction of 26S proteasome but a 19S proteasome increase. NT:
non-transgenic rats; TG: mutant UBQLN2-P497H rats; 26S-RP1/26S-RP2: 26S containing one or two regulatory subunits.




Figure 6. Mutant UBQLN2 does not lead to proteasome impairment in HEK-293T cells. Cells were transfected with either 
wild-type UBQLN2 or with ALS/FTD-linked UBQLN2 mutants and harvested cells in 48 h after transfection. (A). The chart 
revealed that the overall activity of proteasomes was measured using the Suc-AMC substrate, and the immunoblot assay 
showed similar expression levels for the wild-type and mutant UBQLN2 transfections. (B). The in-gel assay assessment 
revealed that 26S proteasome assembly was not impaired in mutant UBQLN2 transfected cells. 
3. Discussion 
The UBQLN2 protein shuttles between the nucleus and cytoplasm and is associated 
with protein degradation via both proteasomes and autophagy [12,14,21]. Proteasome im-
pairment has been implicated in the pathogenesis of UBQLN2-associated ALS/FTD 
[1,6,16]. Here, we demonstrated that an ALS/FTD-linked UBQLN2 mutant impaired as-
sembly of the 26S proteasome in rats and also dissociated the 26S proteasome in vitro. 
Increasingly, ALS/FTD-linked UBQLN2 mutations have been shown to cause defec-
tive protein degradation by [1,15,16,27]. Combined with our recent report that a UBQLN2 
mutant was responsible for the accumulation of the proteasome subunit Rpt1 [26], these 
findings suggest that UBQLN2 mutations can lead to impairment of proteasome functions. 
Consistent with these reports, we found that the 26S proteasome decreased dramatically 
in rats at the age of 4 weeks, even though the overall proteasome activity in this model 
system was unchanged until the age of 20 weeks, at which time proteasome impairment 
deteriorated in concert with disease progression. These findings further support the idea 
that mutant UBQLN2 impairs proteasomes. We previously reported that mutant UBQLN2 
caused neuronal loss to occur in rats at the age of 130 days instead of 50 days, and 
UBQLN2 depletion did not cause any detectable alteration at the age of 280 days [6]. Con-
sistently, we observed no differences for both overall proteasome activity and proteasome 
assembly in UBQLN2-depleted rats as old as 18 months, suggesting that impaired pro-
teasome assembly due to the UBQLN2 mutation precedes their neuronal loss and provid-
ing further evidence for a gain-of-toxicity function that causes neurodegeneration. 
Protein aggregation is one of the prominent features in Ubqln2-linked ALS/FTD [1], 
and rodent models overexpressing mutant UBQLN2 also demonstrated this [4,6,7]. The 
aggregated UBQLN2 protein was found to accumulate in both the cytoplasm and nuclei 
in our mutant UBQLN2 rats [6]. In these rodent models, mutant UBQLN2 entraps these 
proteasome components, and thus may prevent these subunits from assembly into func-
tional proteasomes and lose their ability to perform normal functions. Similar to previous 
reports, we found that a variety of proteasome components, including 20S core particles 
(PSMA1 and PSMB7), 19S regulatory particles (Rpt1 and Rpn1), and mutant UBQLN2 
protein were enriched in nuclei of old mutant UBQLN2 rats compared to those from one-
month-old rats, indicating that this ALS/FTD-linked UBQLN2 mutant caused their mislo-
calization and that these abnormal accumulations were likely responsible for the age-de-
pendent proteasome impairment. 
Figure 6. Mutant UBQLN2 does not lead to proteasome impairment in HEK-293T cells. Cells were transfected with either
wild-type UBQLN2 or with ALS/FTD-linked UBQLN2 mutants and harvested cells in 48 h after transfection. (A). The chart
revealed that the overall activity of proteasomes was meas red using the Suc-AMC substrate, and the immunoblot assay
showed similar expressi n levels for the wild-type and mutant UBQLN2 transfections. (B). The in-gel assay assessment
revealed that 26S proteasome assembly was not impaired in mutant UBQLN2 transfected cells.
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3. Discussion
The UBQLN2 protein shuttles between the nucleus and cytoplasm and is associated
with protein degradation via both proteasomes and autophagy [12,14,21]. Proteasome im-
pairment has been implicated in the pathogenesis of UBQLN2-associated ALS/FTD [1,6,16].
Here, we demonstrated that an ALS/FTD-linked UBQLN2 mutant impaired assembly of
the 26S proteasome in rats and also dissociated the 26S proteasome in vitro.
Increasingly, ALS/FTD-linked UBQLN2 mutations have been shown to cause defec-
tive protein degradation by [1,15,16,27]. Combined with our recent report that a UBQLN2
mutant was responsible for the accumulation of the proteasome subunit Rpt1 [26], these
findings suggest that UBQLN2 mutations can lead to impairment of proteasome functions.
Consistent with these reports, we found that the 26S proteasome decreased dramatically
in rats at the age of 4 weeks, even though the overall proteasome activity in this model
system was unchanged until the age of 20 weeks, at which time proteasome impairment
deteriorated in concert with disease progression. These findings further support the idea
that mutant UBQLN2 impairs proteasomes. We previously reported that mutant UBQLN2
caused neuronal loss to occur in rats at the age of 130 days instead of 50 days, and UBQLN2
depletion did not cause any detectable alteration at the age of 280 days [6]. Consistently, we
observed no differences for both overall proteasome activity and proteasome assembly in
UBQLN2-depleted rats as old as 18 months, suggesting that impaired proteasome assembly
due to the UBQLN2 mutation precedes their neuronal loss and providing further evidence
for a gain-of-toxicity function that causes neurodegeneration.
Protein aggregation is one of the prominent features in Ubqln2-linked ALS/FTD [1],
and rodent models overexpressing mutant UBQLN2 also demonstrated this [4,6,7]. The
aggregated UBQLN2 protein was found to accumulate in both the cytoplasm and nuclei in
our mutant UBQLN2 rats [6]. In these rodent models, mutant UBQLN2 entraps these pro-
teasome components, and thus may prevent these subunits from assembly into functional
proteasomes and lose their ability to perform normal functions. Similar to previous reports,
we found that a variety of proteasome components, including 20S core particles (PSMA1
and PSMB7), 19S regulatory particles (Rpt1 and Rpn1), and mutant UBQLN2 protein were
enriched in nuclei of old mutant UBQLN2 rats compared to those from one-month-old
rats, indicating that this ALS/FTD-linked UBQLN2 mutant caused their mislocalization
and that these abnormal accumulations were likely responsible for the age-dependent
proteasome impairment.
Protein mislocalization is observed in our rat models that overexpress mutant UBQLN2
either in brain neurons [6] or in spinal motor neurons [5] or in astrocytes [5]. It is also
observed in several mouse models reported by different groups. Viral expression of mutant
UBQLN2 in mice showed that WT UBQLN2 was mainly cytoplasmic and diffuse, and
mutant UBQLN2 exhibited prominent nuclear localization [28]. UBQLN2 driven by the
neuron-specific Thy1.2 expression cassette in mice showed that UBQLN2 mutants rather
than wild-type form led to cytoplasmic TDP-43 aggregation [7]. In addition, UBQLN2
driven by the mouse prion promoter in mice revealed that P506T-UBQLN2 resulted in
mislocalization of TDP-43 and sequestration of proteasome subunits [8,29]. Taken together,
these reports indicate that protein mislocalization is a hallmark in ALS/FTD-linked with
UBQLN2 mutations, at least in rodent models.
UBQLN2 is a shuttle protein that facilitates the proteasome to degrade ubiquitinated
proteins [17]. Fully functional proteasomes consist of one 20S core particle and either one
or two 19S regulatory particles [18–20]. Compared to the 20S particle, the 26S proteasome is
more important for protein homeostasis and is therefore more relevant to disease progres-
sion, as shown by our in vivo result that proteasome assembly is impaired at early stages
of the disease in mutant UBQLN2 rats. Consistently, we obtained similar results from the
in vitro proteasome dissociation assay: 26S-RP2 was dramatically reduced but 19S was
greatly increased after three hours of coincubation with purified 26S and mutant UBQLN2
native protein lysates. The in vitro assay results suggest that the UBQLN2 mutation is
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responsible for dissociating the 26S proteasome into 20S and 19S particles, further evidence
that mutant UBQLN2 impaired proteasome integrity.
Consistent with the present findings in HEK-293T cells, a recent study reported no
dysfunction of the proteasome examined by the Suc-AMC substrate in Hela cells that over-
expressed ALS/FTD-linked UBQLN2 mutants (P497H, P497S, P506T, P509S, or P525S) [16].
In addition, the present in-gel assay results also showed no impairment of proteasome as-
sembly. There maybe two reasons for discrepancies between the in vitro and in vivo results.
The first is that mutant UBQLN2 was only expressed in neurons in our in vivo rat model,
and neurons are known to be more vulnerable to damage compared to other cells. The
other potential reason is that both ALS and FTD are age-dependent disorders characterized
by the slow and progressive loss of neurons in the central nervous system [30]. Therefore,
the temporary over-expression of ALS/FTD-linked UBQLN2 mutants in HEK-293T or Hela
cells may not have been sufficient to cause any overt proteasome alterations.
Taken together, the present data suggest that impairment of proteasome integrity
occurs during early stages of the disease process associated with UBQLN2 mutations,
and that these early-stage changes are more relevant to disease progression compared to
late-stage alterations, at least in rat models. These novel findings may therefore contribute
to a novel strategy for early disease diagnosis and to a promising therapeutic approach
that targets proteasome integrity for these incurable disorders.
4. Materials and Methods
4.1. Genotyping of Transgenic Rats
All rats were maintained on Sprague-Dawley background. As characterized previ-
ously [6], CaMKα2-tTA transgenic rats [31] were crossed with TRE-UBQLN2P497H trans-
genic rats to generate bigenic rats. Breeding rats were fed doxycycline (DOX) (50 µg/mL)
(Sigma, St Louis, MI, USA) in drinking water during embryonic development. The DOX
was removed from their drinking water at birth to induce the expression of mutant
UBQLN2P497H transgene. The followed primers were used for the identification of trans-
genic rats: CaMKα2-tTA (5′-GAAGCCCTATTTCTAGCTGTC-3′ and 5′-CTAAATGCCACA
GGGTCTTGC-3′) and TRE-UBQLNP497H (5′-AGGATCATAATCAGCCATACCAC-3′ and 5′-
CTGCACCTAGTGAAACCACGA-3′). The UBQLN2 knock-out rats were identified using
the PCR and the primers: (5′-CAGCAGTTCAAGGAAGCGAT-3′ and 5′-CGTGGTCGTCG
TGCTCGTTC-3′).
4.2. Plasmid Construction and Cell Culture
Plasmids were constructed as previously described [31], and a 3× FLAG tag was fused
to the C-terminal of human UBQLN2. HEK-293T cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA) and were cultured in Dulbecco’s modified
Eagle medium supplemented with 10% fetal bovine serum (FBS) and antibiotics (ampicillin
and streptomycin). Plasmids were transfected using lipofectamine-2000 according to the
manufacturer’s instructions (Life Technologies, Grand Island, NY, USA).
4.3. Cell Fractionation
Rat tissues were fractionated with a modified protocol [32]. Tissues were homogenized
in ice-cold PBS and then centrifuged (10 min, 13,000 rpm in a benchtop centrifuge, at 4 ◦C),
discarded the supernatant; The pellets were resuspended in 1 mL of Buffer A (50 mM
K-HEPES (pH 7.5), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, and 0.5% Triton
X-100 plus complete protease inhibitors). Of this cell suspension 200 µL was then sonicated
and centrifuged at 13,000 rpm for 5 min, kept the supernatant representing the whole tissue
lysate. The remaining 800 µL of the cell suspension was incubated on ice for 10 min and
then centrifuged at 13,000 rpm for 5 min to obtain a cytoplasmic supernatant and a nuclear
pellet. The nuclear pellet was washed with Buffer A and resuspended in 800 µL Buffer B
(Buffer A + 1 M sucrose), and then centrifuged for 10 min at 6000 rpm. All pellets were
resuspended in 300 µL Buffer C (50 mM K-HEPES (pH 7.5), 400 mM KCl, 1.5 mM MgCl2,
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1 mM EDTA, 1 mM EGTA, and 10% glycerol plus complete protease inhibitors), sonicated,
and then centrifuged at 6000 rpm for 10 min with the supernatants as the nuclear fractions.
4.4. SDS-PAGE Electrophoresis and Fluorescence Staining
Total protein lysates from rat tissues were extracted with 1× RIPA buffer and separated
via SDS-PAGE for immunoblotting as described previously [33]. The resolved proteins
were transferred onto nitrocellulose membranes and detected using the following primary
antibodies: mouse anti-Ubqln2 (Abnova; Taipei, Taiwan), mouse anti-Flag (Sigma, St Louis,
MI, USA), and the followed antibodies were purchased form Proteintech (Rosemont, IL,
USA): rabbit anti-P62, rabbit anti-PSMA1, rabbit anti-PSMB7, rabbit anti-Rpt1, rabbit
anti-Rpn1, rabbit anti-Histone 3, and mouse anti-GAPDH. Rat brains were fixed in 4%
paraformaldehyde and then cryopreserved using 30% sucrose prior to cryostat sections.
Tissues were sectioned transversely (20 µm) and stained using the rabbit anti-PSMB7.
4.5. Proteasome Activity Assays and Native-PAGE Electrophoresis
Native protein lysates were extracted from both rat forebrains and transfected cells
using lysis buffer (50 mM Tris.HCl (pH 7.5), 5 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA, 10%
glycerol plus 4 mM ATP, 1 mM DTT, and 1× protease inhibitor). Proteasome activity in total
tissue lysates was measured using proteasome assay buffer (50 mM Tris.HCl (pH 7.5), 5 mM
MgCl2 plus 1 mM ATP, and 1 mM DTT) containing the fluorogenic substrate Boc-LRR-
AMC (Boc-AMC), Suc-LLVY-AMC (Suc-AMC), or Z-LLE-AMC (Z-AMC) (purchased from
UBPBIO.COM) (Aurora, CO, USA) for determining trypsin-, chymotrypsin-, or caspase-
like proteasome activity, respectively. Of total lysates 50 µg were incubated with 50 µM
proteasome substrate for 30 min at 37 ◦C. Then the fluorescence intensity was measured
using a fluorescent plate reader (380 nm excitation/460 nm emission).
NativePAGE™ 3–12% Bis-Tris protein gels were used for the in-gel peptidase activity
assays. Of total protein lysates 50 µg were first resolved at 100 V for 1 h and then at 150 V
for an additional 2 h in a cold room. The gels were then incubated in proteasome assay
buffer containing 50 µM Suc-AMC for 15 min at 37 ◦C. AMC release was visualized under
UV light.
4.6. Proteasome Dissociation Assay
The dissociation assay was performed using proteasome assay buffer (50 mM Tris.HCl
(pH 7.5), 5 mM MgCl2 plus 1 mM ATP, and 1 mM DTT). Purified 26S proteasome (4 µg)
was incubated in this buffer with 40 µg of total protein lysates from rat frontal cortex in
50 µL total volume, and collected 10 µL sample for Native-PAGE analysis at the indicated
time points and stopped the reaction by freezing these reactions on dry ice, followed by the
in-gel assay, and for the immunoblot analysis using the indicated antibodies. The overall
proteasome activity was measured immediately using 5 µL samples at each time point.
4.7. Statistical Analysis
All data shown are representative and all experiments were repeated at least three
times independently. Statistical analysis was carried out using one-way ANOVA test.
p < 0.05 was considered statistically significant.
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